Novartis: promising phase 3 results in SMA
(CercleFinance.com) - Novartis announced on Thursday that the results of a phase 3 study on its Zolgensma gene therapy have shown encouraging results in the treatment of the most severe form of type 1 SMA (spinal muscular atrophy).
The Swiss laboratory says that nearly two-thirds of the participants (65.6%) in the study benefited from an improvement in their motor function, which has never been seen in patients with the disease.
In addition, more than two-thirds of patients (66.7%) no longer needed assistance to feed themselves, which is a key indicator of the stabilisation of or halt to disease progression according to Novartis.
This data was released at the World Muscle Society (WMS) 2020 Virtual Congress.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The Swiss laboratory says that nearly two-thirds of the participants (65.6%) in the study benefited from an improvement in their motor function, which has never been seen in patients with the disease.
In addition, more than two-thirds of patients (66.7%) no longer needed assistance to feed themselves, which is a key indicator of the stabilisation of or halt to disease progression according to Novartis.
This data was released at the World Muscle Society (WMS) 2020 Virtual Congress.
Copyright (c) 2020 CercleFinance.com. All rights reserved.